Researchers
Aurelien Delluc

Aurelien Delluc

MD, Ph. D.

Scientist, Inflammation and Chronic Disease

Ottawa Hospital Research Institute

Contact

adelluc@toh.ca

6137378899 ext 79084

ORCID 0000-0003-0227-1245

Bio

Dr. Aurélien Delluc is a clinician-scientist and a Faculty of Medicine, Department of Medicine, OHRI, Tier 1 Research Chair in Innovative Strategies in Venous Thromboembolism at the Ottawa Hospital Research Institute and a Full Professor in the Department of Medicine at the University of Ottawa. After training in France and completing a PhD focused on common risk factors between arterial and venous thromboembolism, Dr. Delluc moved to Canada in 2018 to join the Division of Hematology and Thrombosis. He brings a translational vision to his clinical and academic work, integrating evidence-based medicine, randomized trials, and population-level data to improve patient outcomes in thrombosis care.


Research Goals and Interests

Dr. Delluc’s research program focuses on improving the diagnosis, treatment, and long-term management of venous thromboembolism (VTE). His work centers on conducting pragmatic, international randomized trials that go beyond anticoagulation to explore novel strategies such as cancer screening, statin therapy, and bleeding risk mitigation. Dr. Delluc is particularly committed to fostering innovation in thrombosis research through mentoring, interdisciplinary collaboration, and patient engagement.

Dr. Delluc is the nominated principal investigator of two CIHR-funded international randomized controlled trials: SOME2, evaluating PET/CT cancer screening after unprovoked VTE, and SAVER, testing statins for secondary prevention of VTE. He also serves as co-principal investigator on the AIRPORT-MPN trial and co-investigator on RADIANT. He is an active mentor, supervising numerous trainees across disciplines and contributing to research capacity-building within the Thrombosis Program and OHRI.

News

Publications

A Multicenter Prospective Cohort Study on the Use of Weight‐Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer‐Associated Venous Thromboembolism—The WAVe Study

2026-01-01 Go to publication

Exposure to Computed Tomography Before Pregnancy and Risk for Pregnancy Loss and Congenital Anomalies

2025-11-01 Go to publication

Outpatient Management of Cancer-Associated Pulmonary Embolism: A Systematic Review and Meta-Analysis

2024-11-27 Go to publication

Obesity as a Predictor for Pulmonary Embolism and Performance of the Age-Adjusted D-Dimer Strategy in Obese Patients with Suspected Pulmonary Embolism

2024-01-01 Go to publication

TILE pilot trial study protocol: Tinzaparin Lead-in to Prevent the Post-Thrombotic syndrome study protocol

2023-10-01 Go to publication
View More on ORCiD

Since his arrival in Ottawa in 2018, Dr Delluc has secured over $9.9 million in research funding, with over $7.4 million as a principal investigator, mainly through grants from CIHR.

Related Research at The Ottawa Hospital